Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2007 Mar 24;369(9566):1000-15.
doi: 10.1016/S0140-6736(07)60460-7.

The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial

Anthony G Marson  1 , Asya M Al-Kharusi, Muna Alwaidh, Richard Appleton, Gus A Baker, David W Chadwick, Celia Cramp, Oliver C Cockerell, Paul N Cooper, Julie Doughty, Barbara Eaton, Carrol Gamble, Peter J Goulding, Stephen J L Howell, Adrian Hughes, Margaret Jackson, Ann Jacoby, Mark Kellett, Geoffrey R Lawson, John Paul Leach, Paola Nicolaides, Richard Roberts, Phil Shackley, Jing Shen, David F Smith, Philip E M Smith, Catrin Tudur Smith, Alessandra Vanoli, Paula R Williamson; SANAD Study group
Affiliations
Randomized Controlled Trial

The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial

Anthony G Marson et al. Lancet. .

Abstract

Background: Carbamazepine is widely accepted as a drug of first choice for patients with partial onset seizures. Several newer drugs possess efficacy against these seizure types but previous randomised controlled trials have failed to inform a choice between these drugs. We aimed to assess efficacy with regards to longer-term outcomes, quality of life, and health economic outcomes.

Methods: SANAD was an unblinded randomised controlled trial in hospital-based outpatient clinics in the UK. Arm A recruited 1721 patients for whom carbamazepine was deemed to be standard treatment, and they were randomly assigned to receive carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate. Primary outcomes were time to treatment failure, and time to 12-months remission, and assessment was by both intention to treat and per protocol. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN38354748.

Findings: For time to treatment failure, lamotrigine was significantly better than carbamazepine (hazard ratio [HR] 0.78 [95% CI 0.63-0.97]), gabapentin (0.65 [0.52-0.80]), and topiramate (0.64 [0.52-0.79]), and had a non-significant advantage compared with oxcarbazepine (1.15 [0.86-1.54]). For time to 12-month remission carbamazepine was significantly better than gabapentin (0.75 [0.63-0.90]), and estimates suggest a non-significant advantage for carbamazepine against lamotrigine (0.91 [0.77-1.09]), topiramate (0.86 [0.72-1.03]), and oxcarbazepine (0.92 [0.73-1.18]). In a per-protocol analysis, at 2 and 4 years the difference (95% CI) in the proportion achieving a 12-month remission (lamotrigine-carbamazepine) is 0 (-8 to 7) and 5 (-3 to 12), suggesting non-inferiority of lamotrigine compared with carbamazepine.

Interpretation: Lamotrigine is clinically better than carbamazepine, the standard drug treatment, for time to treatment failure outcomes and is therefore a cost-effective alternative for patients diagnosed with partial onset seizures.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study flow diagram for SANAD arm A *Three patients did not take drug but did not have seizure data.
Figure 2
Figure 2
Time to treatment failure for whole recruitment period (A) and recruitment after June, 2001 (B) *HR greater than 1 indicates that failure takes place more rapidly on drug compared with baseline.†Analysis for oxcarbazepine use data only from patients randomised after June 1, 2001.
Figure 3
Figure 3
Time to 12-month remission for whole recruitment period (A) and recruitment after June, 2001 (B) *HR greater than 1 indicates that failure takes place more rapidly on drug compared with baseline.†Analysis for oxcarbazepine use data only from patients randomised after June 1, 2001.
See this image and copyright information in PMC

Comment in

References

    1. Hauser WA, Hesdorffer DC. Epilepsy: frequency, causes and consequences. New York: Demos Publications; 1990.
    1. Annegers JF, Hauser WA, Elveback LR. Remission of seizures and relapse in patients with epilepsy. Epilepsia. 1979;20:729–37. - PubMed
    1. Cockerell OC, Johnson AL, Sander JW, Hart YM, Shorvon SD. Remission of epilepsy: results from the National General Practice Study of Epilepsy. Lancet. 1995;346:140–44. - PubMed
    1. London: National Institute for Clinical Excellence; 2004. The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. (Clinical Guideline 20).
    1. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs i: treatment of new onset epilepsy: report of the therapeutics and technology assessment subcommittee and quality standards subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 2004;62:1252–60. - PubMed

Publication types

Substances

Associated data